Theranostics for personalized cancer care

Empowering precision oncology

Theranostics is an innovative concept of personalized therapy that focuses on both the accurate selection of patients and providing them with targeted radioligand therapy to improve their prognosis. It refers to structurally similar diagnostic and therapeutic agents that share a molecular-specific target that involves the use of molecular imaging techniques to identify, personalize, and monitor therapy response. It makes use of pharmaceuticals, such as radioligands, to target and treat specific areas.

Theranostics in comprehensive cancer care demands precision at every step of the patient care pathway.

There is no one-size-fits-all approach to theranostics, so no matter where your institution is on its theranostics journey, we want to empower you with the tools you need to plan, implement, and expand your program to meet the demands of tomorrow.

Clinical image gallery

Molecular imaging plays a role in personalizing treatment for prostate cancer, liver cancer, neuroendocrine tumors, and thyroid cancer.

Prostate cancer

Liver cancer

Neuroendocrine tumors

Thyroid cancer

Theranostics for prostate cancer (PSMA)

15-minute, whole-body SPECT/CT with xSPECT Quant provides high sensitivity to assess ¹⁷⁷Lu-PSMA therapy response

Patient with a history of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) underwent 6 cycles of ¹⁷⁷Lu-PSMA treatment
Cycle 6 ,¹⁷⁷Lu-PSMA, 3-bed position xSPECT Quant imaging confirmed positive treatment response
There is an overall increased extent of PSMA-avid cervical, thoracic, and abdominopelvic nodal metastasis

Read the complete case study

theranostics nuclear medicine liver cancer scan

Theranostics for liver cancer

SPECT/CT evaluation of liver tumor perfusion with hepatic arterial catheter infusion of ^99mTc-MAA prior to SIRT

Patient with hepatocellular carcinoma evaluated for⁹⁰Y-microsphere radioembolization, selective internal radiation therapy (SIRT)
SPECT/CT following infusion of ^99mTc MAA through hepatic arterial catheter to evaluate liver tumor perfusion and lung shunt fraction
Study shows perfusion limited to the periphery of large tumor with large central necrosis, which shows absence of any perfusion
Low-dose CT sharply delineates necrotic tumor margin, highlighting the adjacent tracer uptake

neuroendocrine tumors nuclear medicine theranostics scan

Theranostics for neuroendocrine tumors

⁶⁴Cu-DOTATATE PET/CT delineates multiple neuroendocrine tumor metastases for precise diagnosis and patient therapy selection

80-year-old male with ascities, abdominal pain, and weight loss. CT revealed peritoneal and mesenteric nodules. Pathology confimed well-differentiated neuroendocrine tumor. Patient referred for PET/CT staging for therapy decision.
⁶⁴Cu-DOTATATE PET/CT shows high contrast within metatstatic lesions throughout the chest, abdomen, and pelvis, suggesting possibility of success with radionuclide therapy

Theranostics for thyroid cancer

¹³¹I xSPECT Quant enables quantification of residual thyroid tissue to determine therapeutic dose

SPECT/CT with xSPECT Quant acquisition performed 24 hours following a diagnostic dose of ¹³¹I in a patient with a thyroid carcinoma post total thyroidectomy to determine accurate ¹³¹I therapeutic dose
xSPECT Quant-based calculation of absolute tracer concentration shows high ¹³¹I concentration in residual thyroid tissue with SUV_max of 10.29
¹³¹I xSPECT Quant enables quantification of residual tissue to determine therapeutic dose

The outcomes achieved by the Siemens Healthineers customers described herein were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (eg, hospital size, case mix, level of IT adoption) there can be no guarantee that others will achieve the same results.

Theranostics for personalized cancer care

Read real life stories

A physician’s experience

A patient’s experience

Clinical image gallery

Theranostics for prostate cancer (PSMA)

Theranostics for liver cancer

Theranostics for neuroendocrine tumors

Theranostics for thyroid cancer

We are committed to personalizing theranostics solutions for you, so you can focus on personalizing care for patients.

Are you interested?

Contact Us

Share

Learn more

You are entering a global domain of Siemens Healthineers.